An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia

Summary

The purpose of this study is to determine the safety and effectiveness of ulocuplumab in combination with low dose cytarabine in the treatment of Newly Diagnosed Acute Myeloid Leukemia (AML).

Timeline

Start

2015-01-27

Primary completion

2019-06-04

Completion

2019-06-04

Outcome

Outcome not reported

Stopped (Enrollment): “Business objectives have changed, slow accrual, the standard of care for the patient population changed and we were unable to accrue any longer.”

Drugs

Indications